|
Gene: ZNF609 |
Gene summary for ZNF609 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ZNF609 | Gene ID | 23060 |
Gene name | zinc finger protein 609 | |
Gene Alias | ZNF609 | |
Cytomap | 15q22.31 | |
Gene Type | protein-coding | GO ID | GO:0001764 | UniProtAcc | O15014 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23060 | ZNF609 | Dong_P5 | Human | Prostate | Tumor | 2.25e-08 | -5.42e-03 | 0.053 |
23060 | ZNF609 | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 1.62e-06 | 4.97e-01 | 0.1633 |
23060 | ZNF609 | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 6.84e-08 | 4.83e-01 | 0.1608 |
23060 | ZNF609 | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 3.16e-03 | 3.89e-01 | 0.1604 |
23060 | ZNF609 | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 4.41e-03 | 3.24e-01 | 0.1575 |
23060 | ZNF609 | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 9.09e-04 | 3.45e-01 | 0.1545 |
23060 | ZNF609 | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 2.53e-02 | 3.26e-01 | 0.1569 |
23060 | ZNF609 | male-WTA | Human | Thyroid | PTC | 2.37e-13 | 1.76e-01 | 0.1037 |
23060 | ZNF609 | PTC01 | Human | Thyroid | PTC | 1.81e-07 | 1.22e-01 | 0.1899 |
23060 | ZNF609 | PTC03 | Human | Thyroid | PTC | 1.40e-04 | 3.46e-01 | 0.1784 |
23060 | ZNF609 | PTC04 | Human | Thyroid | PTC | 3.32e-09 | 2.64e-01 | 0.1927 |
23060 | ZNF609 | PTC05 | Human | Thyroid | PTC | 9.23e-12 | 3.47e-01 | 0.2065 |
23060 | ZNF609 | PTC06 | Human | Thyroid | PTC | 1.46e-23 | 4.09e-01 | 0.2057 |
23060 | ZNF609 | PTC07 | Human | Thyroid | PTC | 8.99e-19 | 3.15e-01 | 0.2044 |
23060 | ZNF609 | ATC09 | Human | Thyroid | ATC | 1.29e-03 | 1.58e-01 | 0.2871 |
23060 | ZNF609 | ATC11 | Human | Thyroid | ATC | 5.07e-05 | 3.24e-01 | 0.3386 |
23060 | ZNF609 | ATC12 | Human | Thyroid | ATC | 2.25e-07 | 1.54e-01 | 0.34 |
23060 | ZNF609 | ATC13 | Human | Thyroid | ATC | 4.36e-14 | 2.73e-01 | 0.34 |
23060 | ZNF609 | ATC1 | Human | Thyroid | ATC | 2.52e-05 | 2.37e-01 | 0.2878 |
23060 | ZNF609 | ATC2 | Human | Thyroid | ATC | 2.35e-07 | 7.83e-01 | 0.34 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00075173 | Cervix | CC | muscle organ development | 58/2311 | 327/18723 | 2.73e-03 | 1.85e-02 | 58 |
GO:20012241 | Cervix | CC | positive regulation of neuron migration | 6/2311 | 16/18723 | 9.35e-03 | 4.66e-02 | 6 |
GO:00075174 | Endometrium | AEH | muscle organ development | 60/2100 | 327/18723 | 8.19e-05 | 1.22e-03 | 60 |
GO:00017642 | Endometrium | AEH | neuron migration | 31/2100 | 156/18723 | 1.08e-03 | 9.46e-03 | 31 |
GO:000751712 | Endometrium | EEC | muscle organ development | 59/2168 | 327/18723 | 3.49e-04 | 3.85e-03 | 59 |
GO:00017641 | Endometrium | EEC | neuron migration | 33/2168 | 156/18723 | 4.17e-04 | 4.38e-03 | 33 |
GO:2001224 | Liver | HCC | positive regulation of neuron migration | 14/7958 | 16/18723 | 2.73e-04 | 1.98e-03 | 14 |
GO:0001764 | Lung | IAC | neuron migration | 31/2061 | 156/18723 | 7.89e-04 | 1.02e-02 | 31 |
GO:0007517 | Lung | AAH | muscle organ development | 22/613 | 327/18723 | 1.20e-03 | 3.33e-02 | 22 |
GO:00075176 | Oral cavity | EOLP | muscle organ development | 57/2218 | 327/18723 | 1.76e-03 | 1.15e-02 | 57 |
GO:000751714 | Oral cavity | NEOLP | muscle organ development | 56/2005 | 327/18723 | 2.65e-04 | 2.70e-03 | 56 |
GO:00017643 | Oral cavity | NEOLP | neuron migration | 31/2005 | 156/18723 | 4.96e-04 | 4.40e-03 | 31 |
GO:00075175 | Prostate | BPH | muscle organ development | 71/3107 | 327/18723 | 9.00e-03 | 3.84e-02 | 71 |
GO:000751713 | Prostate | Tumor | muscle organ development | 74/3246 | 327/18723 | 8.03e-03 | 3.54e-02 | 74 |
GO:000751716 | Thyroid | ATC | muscle organ development | 139/6293 | 327/18723 | 4.45e-04 | 2.64e-03 | 139 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF609 | SNV | Missense_Mutation | c.781C>T | p.Pro261Ser | p.P261S | O15014 | protein_coding | deleterious(0.02) | probably_damaging(0.964) | TCGA-AN-A0AJ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ZNF609 | SNV | Missense_Mutation | novel | c.457N>A | p.Val153Ile | p.V153I | O15014 | protein_coding | tolerated(0.32) | benign(0.003) | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF609 | SNV | Missense_Mutation | c.952G>C | p.Val318Leu | p.V318L | O15014 | protein_coding | deleterious(0) | probably_damaging(0.935) | TCGA-D8-A1JT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
ZNF609 | SNV | Missense_Mutation | rs756586641 | c.389N>G | p.Asn130Ser | p.N130S | O15014 | protein_coding | tolerated(0.89) | benign(0.001) | TCGA-E2-A152-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | PD |
ZNF609 | SNV | Missense_Mutation | c.3647C>G | p.Ser1216Cys | p.S1216C | O15014 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
ZNF609 | SNV | Missense_Mutation | novel | c.3103N>T | p.Ala1035Ser | p.A1035S | O15014 | protein_coding | tolerated(1) | benign(0) | TCGA-E9-A3X8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphane | CR |
ZNF609 | SNV | Missense_Mutation | novel | c.164A>G | p.Lys55Arg | p.K55R | O15014 | protein_coding | tolerated(0.06) | probably_damaging(0.99) | TCGA-EW-A1P4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
ZNF609 | SNV | Missense_Mutation | novel | c.43N>A | p.Ala15Thr | p.A15T | O15014 | protein_coding | tolerated(0.27) | benign(0.005) | TCGA-OL-A97C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ZNF609 | insertion | Frame_Shift_Ins | novel | c.3302_3303insACAAGAAGGCAGAGATGGGCCTGAAGGAGCGG | p.Ser1102GlnfsTer17 | p.S1102Qfs*17 | O15014 | protein_coding | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
ZNF609 | SNV | Missense_Mutation | novel | c.1160N>T | p.Ala387Val | p.A387V | O15014 | protein_coding | deleterious(0.04) | benign(0.017) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |